புற்றுநோயியல் நியூகோ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

bluebird bio to separate oncology and rare diseases units
New oncology company will be led by current bluebird bio CEO Nick Leschly
bluebird bio has announced plans to spin out its oncology unit into a new company (“Oncology Newco”) while it will remain focused on developing gene therapies for rare diseases.
Oncology Newco will be established as an independent organisation and will be led by bluebird bio’s current chief executive officer Nick Leschly.
bluebird bio, which will retain its focus on severe genetic diseases (SGD), will be headed by the current president of the company’s SGD business Andrew Obenshain, with Leschly set to take on the role of executive chair. ....

Andrew Obenshain , Nick Leschly , Oncology Newco , Bristol Myers Squibb Partnered , ஆண்ட்ரூ ஓபென்ஷ்ைன் , புற்றுநோயியல் நியூகோ , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் கூட்டாளர் ,